Back to Schemes

Sponsored

Lung Cancer (NSCLC) [Plasma]

Supported by

AstraZeneca
MSD

Product Code: 02-LUNGP-27

From £310.00

Deadline to order: 28/02/2027

EGFR and KRAS testing of cfDNA (plasma) for NSCLC. This EQA is sponsored.

Target/Genes:

The scope of this EQA includes testing for actionable and resistant variants in the EGFR and KRAS genes in cfDNA from plasma in Non Small Cell Lung Cancer in the context of Tyrosine Kinase inhibitors and KRAS inhibitors therapies.

Technology:

Any molecular test

Language:

English, French, German, Italian, Spanish

Sample Type:

Plasma (cfDNA)

Accredited:

Pending

Sample dispatch to your laboratory:

Sep-27

Test and Submit Results:

September - November 2027

Final Results and Certificate:

May - June 2028

You can complete purchase on our secure partner site.

How it works

Register

  • Enrol before the closing date (28/02/2027)
  • EMQN ships EQA samples or digital cases

Test & submit results

  • Analyse samples in your routine workflow
  • Upload results via your website account (September - November 2027)

Review & get certified

  • EMQN assesses your data
  • Receive your individual results, EQA summary report & certificate of participation (May - June 2028)

EQA Assessment

The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.

Sample Details

Three mock clinical cases with matching samples will be provided, 3ml artificial / synthetic plasma is provided per case.

Complete information will be available in scheme instructions.

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

The minimum requirement is EGFR testing. If you provide a clinical service for KRAS and/or BRAF testing, this should be included.

Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.

This EQA is supported by an educational grant from AstraZeneca, fees are subsidised so there is a reduced cost for participants. EMQN would like to acknowledge and thank AstraZeneca for this support.

Limited to 320 participants, please register early to avoid disappointment. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc). This EQA is provided in collaboration with GenQA. 

Enquire about this scheme

Contact Information

added wishlist!
View Wishlist

0

View Wishlist

Register Interest

Express your interest in ''.